MRG-106

February 7, 2018February 7, 2018

90% of Mycosis Fungoides Patients Improved After MRG-106 Treatment, Study Shows

News

MRG-106, an RNA-based therapy, induced clinical improvements in 90 percent of patients with mycosis fungoides – a subtype of cutaneous T-cell lymphoma (CTCL) – in a Phase 1 clinical trial testing ... Read more

May 26, 2017May 26, 2017

EU Gives Orphan Drug Status to MRG-106 for Treating T-cell Skin Lymphomas

News

The European Union has granted orphan drug status to miRagen Therapeutics’s MRG-106 for the treatment of cutaneous T-cell lymphoma (CTCL). The status is given to treatments for rare diseases. It accelerates the ... Read more

March 3, 2016March 3, 2016

Cutaneous T-cell Lymphoma Phase 1 Clinical Trial of MiR-155 Inhibitor Now Enrolling Patients

News

miRagen Therapeutics, Inc., announced that it has started a Phase 1 clinical trial (NCT02580552) of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155. The trial’s primary ... Read more